Shares in Aurinia Pharma (AUPH) surged 9% in Tuesday’s extended trading after the U.S. Food and Drug Administration (FDA) accepted the filing of its New Drug Application (NDA) for voclosporin, a potential treatment for lupus nephritis (LN). This is a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus (SLE).Encouragingly, the FDA granted a faster six-month Priority Review for the application (instead of the usual ten months), with a PDUFA decision date set for January 22, 2021.The FDA also told Aurinia that they are not currently planning to hold an advisory committee meeting to discuss the …read more
Source:: Yahoo Finance
